We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.2%
2 Industrials 0.08%
3 Consumer Staples 0.05%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTO
251
DELISTED
Aptose Biosciences, Inc.
APTO
$622K 0.02%
231
+222
+2,467% +$440K
ALBO
252
DELISTED
Albireo Pharma Inc
ALBO
$595K 0.02%
16,883
– –
ARVN icon
253
Arvinas
ARVN
$520M
$558K 0.02%
8,430
+4,214
+100% +$322K
DCTH icon
254
Delcath Systems
DCTH
$450M
$546K 0.02%
43,915
-68,797
-61% -$1.27M
KRRO icon
255
Korro Bio
KRRO
$155M
$536K 0.02%
+1,130
New +$2.2M
PBYI icon
256
Puma Biotechnology
PBYI
$391M
$533K 0.02%
54,901
– –
NVAX icon
257
Novavax
NVAX
$1.22B
$478K 0.02%
2,636
– –
KURA icon
258
Kura Oncology
KURA
$816M
$441K 0.01%
15,603
+4,400
+39% +$139K
VCEL icon
259
CALL
Vericel Corp
VCEL
$2.36B
$439K 0.01%
+7,900
New +$357K
MREO
260
Mereo BioPharma
MREO
$50.4M
$419K 0.01%
1,146,308
– –
SLS icon
261
SELLAS Life Sciences
SLS
$2.21B
$410K 0.01%
+48,053
New +$393K
ABUS icon
262
Arbutus Biopharma
ABUS
$861M
$383K 0.01%
115,000
– –
COGT icon
263
Cogent Biosciences
COGT
$6.64B
$367K 0.01%
41,762
– –
ASMB icon
264
Assembly Biosciences
ASMB
$503M
$334K 0.01%
6,039
– –
CRVS icon
265
Corvus Pharmaceuticals
CRVS
$1.12B
$307K 0.01%
+100,000
New +$361K
RCOR
266
DELISTED
Renovacor, Inc.
RCOR
$301K 0.01%
+30,000
New +$311K
FATE icon
267
Fate Therapeutics
FATE
$291M
$297K 0.01%
+3,600
New +$345K
ASLN
268
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$243K 0.01%
30,613
-19,548
-39% -$2.48M
BTAI icon
269
BioXcel Therapeutics
BTAI
$26.2M
$226K 0.01%
+327
New +$263K
IVA
270
Inventiva
IVA
$1B
$215K 0.01%
15,000
– –
GNCA
271
DELISTED
Genocea Biosciences, Inc.
GNCA
$213K 0.01%
+78,767
New +$233K
ANAB icon
272
AnaptysBio
ANAB
$1.59B
$207K 0.01%
9,553
-90,447
-90% -$2.28M
ARKG icon
273
ARK Genomic Revolution ETF
ARKG
$1.6B
$178K 0.01%
+2,000
New +$198K
INBX
274
DELISTED
Inhibrx, Inc. Common Stock
INBX
$161K 0.01%
8,076
– –
ACAD icon
275
Acadia Pharmaceuticals
ACAD
$4.39B
$155K 0.01%
6,008
-50,000
-89% -$2.2M
9 10
11
12 13

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.